Press Release January 17, 2023

Hippo T&C to Expand Distribution of Digital Therapeutics for ADHD, Depression, and Diabetic Foot Care This Year

#CES2023#AttnKare#BlueKare
Hippo T&C to Expand Distribution of Digital Therapeutics for ADHD, Depression, and Diabetic Foot Care This Year

Hippo T&C to Expand Digital Therapeutics for ADHD, Depression, and Diabetic Foot Care

 

Hippo T&C, established by Professor Tai-Myoung Chung of Sungkyunkwan University's Software Engineering Department in 2020, is set to expand its digital therapeutic offerings following the completion of clinical trials for its ADHD, depression, and diabetic foot care solutions.

 

Hippo T&C's digital therapeutics include:

  • AttnKare: For ADHD diagnosis and treatment.
  • BlueKare: For depression treatment.
  • DfuKare: For diabetic foot care.

 

AttnKare, which received Innovation Awards in the Health & Wellness and Virtual & Augmented Reality categories at CES 2022, continues to gain recognition. This year, Hippo T&C also showcased its technology at CES 2023.

 

AttnKare employs virtual reality (VR) games for diagnosis. It collects data on hand and body movements and gameplay performance during VR missions, analyzing this data with artificial intelligence (AI) to provide a diagnosis and personalized treatment based on international ADHD standards.

 

Professor Chung highlighted, “We analyze 18 aspects of patients' performance in VR games, including focus and social skills, and prescribe FDA-approved therapeutic games. These games are specially designed and developed considering various user profiles.”

 

The ADHD diagnostic content of AttnKare will be distributed to approximately 3,900 psychological centers across South Korea, while its therapeutic content will be supplied to hospitals. Physicians can prescribe the therapeutic content, allowing patients to conduct treatments at home, thus saving time and costs. Data from the treatment process will be sent to a dashboard for continuous monitoring by doctors.

 

 

Hippo T&C Unveils Digital Therapeutics at CES 2023

 

Hippo T&C showcased its digital therapeutics at CES 2023, including:

  • AttnKare: For ADHD diagnosis and treatment.
  • BlueKare: For depression treatment.
  • DfuKare: For diabetic foot care.

 

AttnKare, which was completed last year, is currently undergoing clinical trials with the South Korean Ministry of Food and Drug Safety. Official service is expected to commence later this year upon completion of the trials.

 

BlueKare, the digital therapeutic for depression, will enter clinical trials in February. This app utilizes artificial intelligence to analyze the severity and causes of depression, offering personalized conversations and lifestyle coaching to help users regain vitality. A cute puppy character within the app engages users in conversations and provides coaching through six methods, including meditation, exercise, and deep breathing. The app supports both Korean and English.

 

The puppy character in BlueKare encourages users to perform activities like deep breathing and exercise, which might otherwise seem uninteresting. For example, if a user needs guidance on where to go for a walk, the app uses AI data and smartphone GPS to suggest local coffee shops, recommending, "On a sunny afternoon at 4 p.m., it would be nice to visit a coffee shop."

 

Professor Tai-Myoung Chung, CEO of Hippo T&C, explained, “BlueKare is designed to make basic depression treatments more approachable. The AR feature makes the puppy character feel like it's actually present in the user's space, and the chatbot allows for real-time interactions with the character.”

 

 

Hippo T&C Introduces 'DfuKare' for Preventing Diabetic Foot Amputation

 

Hippo T&C has developed the digital therapeutic DfuKare to prevent amputations due to diabetic foot complications.

 

DfuKare is designed to address the late detection of diabetic foot issues, which can lead to severe outcomes such as amputation. Many patients with diabetes experience foot deterioration over about ten years, often resulting in amputation if not treated promptly. In South Korea, approximately 1,700 people face amputations annually due to untreated diabetic foot conditions.

 

Hippo T&C’s SmarTinsole is a specially designed shoe insole equipped with multiple sensors, including pressure sensors and oxygen saturation sensors. These sensors continuously monitor the condition of the foot and analyze the data using artificial intelligence. This information is accessible through the DfuKare app, allowing users to manage their foot health proactively.

 

The DfuKare system has completed clinical trials at Seoul Boramae Hospital and is preparing for further trials with the Korean Ministry of Food and Drug Safety (MFDS) later this year.

 

Professor Tai-Myoung Chung, CEO of Hippo T&C, stated, “When patients with diabetic foot wear the sensor-equipped insoles, we can observe discrepancies in foot pressure. This helps differentiate diabetic patients and prevents amputations through management strategies such as exercise, massage, skin moisturizing, and blood sugar control.”

 

이나리 기자(narilee@zdnet.co.kr)

source | ZDNet Korea (https://zdnet.co.kr/ )

original press | https://zdnet.co.kr/view/?no=20230116090029

Back to List